Improvements to premium tax credits, enacted in the American Rescue Plan and extended by the Inflation Reduction Act, have ...

PTC Therapeutics' gene therapy is already approved in the European ... alongside the dollar on Thursday as investors bet that ...

A study released in Science determines that just four policies can reduce mismanaged plastic waste—plastic that isn't ...

The uniform adoption of just four waste management policies around the world could eliminate more than 90 percent of the ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $45.00. The company’s shares closed yesterday at ...

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

An enhanced premium tax credit for Marketplace plans will expire at 2025-end. If Congress doesn't act soon, millions may go ...

Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...

Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to today's PTC 2024 fourth quarter conference call. During this presen ...

PTC (NASDAQ:PTC) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect PTC ...

PTC (PTC) announced that its Board of Directors has authorized the repurchase of up to $2B worth of PTC common stock through September 30, 2027. The views and opinions expressed herein are the ...

Analysts expect PTC to report an earnings per share (EPS) of $1.45. PTC bulls will hope to hear the company announce they've ...